According to the findings of four case reports published in the November issue of the Journal of Clinical Psychiatry, the administration of oral synthetic THC is linked with improved symptoms of psychosis in patients with refractory schizophrenia.
Investigators at the Rockland Psychiatric Center in Orangeburg, New York, the Columbia University Medical Center, and the New York University School of Medicine evaluated the efficiency of oral THC (dronabinol) on eight patients with refractory psychosis.
The trial subjects had a history of symptomatic improvement when making use of cannabis and had been unresponsive to conventional medical treatments. It was reported by the researchers that there was significant improvement in four of the eight patients after oral THC treatment. The authors reported, in particular, that administration of cannabinoid produced a significant reduction in subjects’ aggressive tendencies. No patients in the study experienced significant adverse side effects from THC.
“It appears that a predisposed subset of patients with schizophrenia may actually improve with cannabinoid stimulation,” investigators concluded.
The study, “Improvement in refractory psychosis with dronabinol: four case reports,” appeared in the Journal of Clinical Psychiatry.